Trial Profile
Phase II Trial of Concurrent, Split Course Chemoradiation Followed by Durvalumab (MEDI4736) in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ESR1814205
- 07 Sep 2023 Planned End Date changed from 1 Jul 2023 to 31 Oct 2028.
- 07 Sep 2023 Planned primary completion date changed from 1 Jul 2023 to 31 Oct 2026.
- 24 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Jul 2023.